These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

780 related articles for article (PubMed ID: 28940866)

  • 21. Use of acamprosate and opioid antagonists in the treatment of alcohol dependence: a European perspective.
    Soyka M; Chick J
    Am J Addict; 2003; 12(s1):s69-s80. PubMed ID: 14972781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological treatment of alcohol use disorder. Scientific evidence.
    Attilia F; Perciballi R; Rotondo C; Capriglione I; Iannuzzi S; Attilia ML; Vitali M; Alessandrini G; Scamporrino MCM; Fiore M; Ceccanti M;
    Riv Psichiatr; 2018; 53(3):123-127. PubMed ID: 29912214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.
    Gual A; He Y; Torup L; van den Brink W; Mann K;
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1432-42. PubMed ID: 23562264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy.
    Mann K; Torup L; Sørensen P; Gual A; Swift R; Walker B; van den Brink W
    Eur Neuropsychopharmacol; 2016 Dec; 26(12):1941-1949. PubMed ID: 27842940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence.
    Mason BJ; Salvato FR; Williams LD; Ritvo EC; Cutler RB
    Arch Gen Psychiatry; 1999 Aug; 56(8):719-24. PubMed ID: 10435606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opioid antagonists for alcohol dependence.
    Rösner S; Hackl-Herrwerth A; Leucht S; Vecchi S; Srisurapanont M; Soyka M
    Cochrane Database Syst Rev; 2010 Dec; (12):CD001867. PubMed ID: 21154349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacotherapy of alcohol withdrawal: update and new developments].
    Soyka M; Rösner S
    Nervenarzt; 2021 Jan; 92(1):57-65. PubMed ID: 32696076
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical relevance of nalmefene versus placebo in alcohol treatment: reduction in mortality risk.
    Roerecke M; Sørensen P; Laramée P; Rahhali N; Rehm J
    J Psychopharmacol; 2015 Nov; 29(11):1152-8. PubMed ID: 26349557
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opioid Receptor Antagonists in the Treatment of Alcoholism.
    Serecigni JG
    Adicciones; 2015 Sep; 27(3):214-30. PubMed ID: 26437315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene.
    Mann K; Bladström A; Torup L; Gual A; van den Brink W
    Biol Psychiatry; 2013 Apr; 73(8):706-13. PubMed ID: 23237314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials.
    Falk DE; O'Malley SS; Witkiewitz K; Anton RF; Litten RZ; Slater M; Kranzler HR; Mann KF; Hasin DS; Johnson B; Meulien D; Ryan M; Fertig J;
    JAMA Psychiatry; 2019 Apr; 76(4):374-381. PubMed ID: 30865232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review.
    Bouza C; Angeles M; Muñoz A; Amate JM
    Addiction; 2004 Jul; 99(7):811-28. PubMed ID: 15200577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.
    Johnson BA
    Biochem Pharmacol; 2008 Jan; 75(1):34-56. PubMed ID: 17880925
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Trial-Based Predictive Microsimulation Assessing the Public Health Benefits of Nalmefene and Psychosocial Support for the Reduction of Alcohol Consumption in Alcohol Dependence.
    Laramée P; Millier A; Rahhali N; Cristeau O; Aballéa S; François C; Chalem Y; Toumi M; Rehm J
    Appl Health Econ Health Policy; 2016 Aug; 14(4):493-505. PubMed ID: 27283839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medical management of alcohol use disorders].
    Paille F
    Rev Prat; 2019 Oct; 69(8):909-916. PubMed ID: 32237660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Stevenson M; Pandor A; Stevens JW; Rawdin A; Rice P; Thompson J; Morgan MY
    Pharmacoeconomics; 2015 Aug; 33(8):833-47. PubMed ID: 25851485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
    Kranzler HR; Van Kirk J
    Alcohol Clin Exp Res; 2001 Sep; 25(9):1335-41. PubMed ID: 11584154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repurposing drugs for treatment of alcohol use disorder.
    Aubin HJ
    Int Rev Neurobiol; 2024; 175():153-185. PubMed ID: 38555115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy, tolerability and safety of nalmefene as-needed in patients with alcohol dependence: A 1-year, randomised controlled study.
    van den Brink W; Sørensen P; Torup L; Mann K; Gual A;
    J Psychopharmacol; 2014 Aug; 28(8):733-44. PubMed ID: 24671340
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.